Rapport Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 147.63K shares, a 60651.44% increase year-over-year.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 80.87K shares, a 2395.90% increase year-over-year.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 94.53K shares.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 94.85K shares.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 192.86K shares, a 5049.91% increase from fiscal 2024.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 3.75K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 147.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 417.87K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 80.87K shares 10-Q · filed 2026-05-07 | 270.49K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 94.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 192.86K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 94.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | 243.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | |
| 2025-03-31 | 3.24K shares 10-Q · filed 2025-05-08 | |
| 2024-12-31 | 3.75K shares 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |